CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

Rhea-AI Summary

CytoSorbents (NASDAQ: CTSO) said its CEO Dr. Phillip Chan and CFO Peter Mariani will attend the Jefferies Global Healthcare Conference in London on November 18-19, 2025.

Management will participate in one-on-one investor meetings; investors can schedule meetings through the conference website. For investor queries, contact the company investor relations team at ir@cytosorbents.com.

PRINCETON, N.J., Nov. 11, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that its Chief Executive Officer, Dr. Phillip Chan, and Chief Financial Officer, Mr. Peter Mariani, will attend and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference in London on November 18-19, 2025. 

Investors attending the conference can schedule a meeting with management through the conference website.  For more information, please contact the Company's investor relations team at ir@cytosorbents.com.

About Jefferies Global Healthcare Conference in London

The Jefferies Global Healthcare Conference in London is the flagship European healthcare investment gathering organized by Jefferies, one of the world's leading full-service investment banking and capital markets firms.   The conference brings together C-suite executives, investors (public, private equity, venture capital), industry strategists and service-providers across the full spectrum of healthcare — including biotech, pharmaceuticals, medical technology, healthcare services, digital health and healthcare IT.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body.  CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death.  The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure.  In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with nearly 300,000 devices used cumulatively to date.  CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber.  Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures.  CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure.  CytoSorb is not yet approved or cleared in the United States.

In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs.  It has received two FDA Breakthrough Device Designations:  one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery.  The Company is actively pursuing regulatory approval of DrugSorb-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA.  DrugSorb-ATR is not yet granted or approved in either the U.S. or Canada.

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company's website at https://ir.cytosorbents.com/  or follow us on Facebook and X. 

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to our ability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval, the ability to grow sales and cut costs, the outcome of the restructuring of our direct sales team and strategy in Germany, our ability to appropriately finance the Company,  and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2025, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

U.S. Company Contact: 
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
pmariani@cytosorbents.com 

Investor Relations Contact:
Aman Patel, CFA & Adanna G. Alexander, PhD
ICR Healthcare
ir@cytosorbents.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-to-participate-at-the-jefferies-global-healthcare-conference-in-london-302611184.html

SOURCE Cytosorbents Corp

FAQ

When will CytoSorbents (CTSO) management attend the Jefferies Global Healthcare Conference in London?

CytoSorbents management will attend on November 18-19, 2025.

Which CytoSorbents executives (CTSO) will meet investors at the November 2025 Jefferies London conference?

CEO Dr. Phillip Chan and CFO Peter Mariani will participate in one-on-one investor meetings.

How can investors schedule a meeting with CytoSorbents (CTSO) at the Jefferies London conference?

Investors can schedule meetings through the Jefferies Global Healthcare Conference website.

Who should investors contact for more information about CytoSorbents (CTSO) conference meetings?

Contact the investor relations team at ir@cytosorbents.com for more information.

Will CytoSorbents (CTSO) present a public webcast or only one-on-one meetings at the November 18-19, 2025 Jefferies conference?

The announcement states management will participate in one-on-one investor meetings; no public webcast was mentioned.

Can shareholders attend CytoSorbents (CTSO) meetings at the Jefferies Global Healthcare Conference in London?

Shareholders can attend if they are registered with the conference and schedule a meeting via the conference website.